ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AO GENERIUM and Samsung Bioepis side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AO GENERIUMSamsung Bioepis
studies on the registry3133
open to participants now32
phase 3 studies under way31
reach primary completion within a year01
programswith a study of their own in two years34

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAO GENERIUMSamsung Bioepis
Phase 100%

Samsung Bioepis: 2 of its 4 programs at phase 1

  1. ixekizumabphase 1
  2. potassium L-ascorbatephase 1
50%
Phase 2

AO GENERIUM: 1 of its 3 programs at phase 2

  1. GNR-127phase 2
33%

Samsung Bioepis: 2 of its 4 programs at phase 2

  1. Ranibizumabphase 2
  2. afliberceptphase 2
50%
Phase 3

AO GENERIUM: 2 of its 3 programs at phase 3

  1. afliberceptphase 3
  2. Revelise (GENERIUM, Russia)phase 3
67%
00%
Approved, new studies00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AO GENERIUM0 readouts · 0 phase 3············
Samsung Bioepis1 readouts · 0 phase 3·······

Samsung Bioepis, Jun ’27: 1 program whose next study reaches primary completion

  1. ixekizumabphase 1 · Jun 9 · NCT07789964
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AO GENERIUM

New programs 1

  • afliberceptphase 3 · first study · Sep 18 · Macular Degeneration

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Samsung Bioepis

New programs 1

  • afliberceptphase 2 · first study · Sep 21 · Macular Degeneration

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionAO GENERIUMSamsung Bioepis
Macular Degenerationboth · compare here

AO GENERIUM in Macular Degeneration: 1 program

  1. afliberceptphase 3

Their studies: AO GENERIUM’s studies of Macular Degeneration in search

Samsung Bioepis in Macular Degeneration: 2 programs

  1. Ranibizumabphase 2
  2. afliberceptphase 2

Their studies: Samsung Bioepis’s studies of Macular Degeneration in search

Macular Edemaboth · compare here

AO GENERIUM in Macular Edema: 1 program

  1. afliberceptphase 3

Their studies: AO GENERIUM’s studies of Macular Edema in search

Samsung Bioepis in Macular Edema: 2 programs

  1. Ranibizumabphase 2
  2. afliberceptphase 2

Their studies: Samsung Bioepis’s studies of Macular Edema in search

Retinal Vein Occlusionboth · compare here

AO GENERIUM in Retinal Vein Occlusion: 1 program

  1. afliberceptphase 3

Their studies: AO GENERIUM’s studies of Retinal Vein Occlusion in search

Samsung Bioepis in Retinal Vein Occlusion: 2 programs

  1. Ranibizumabphase 2
  2. afliberceptphase 2

Their studies: Samsung Bioepis’s studies of Retinal Vein Occlusion in search

Colorectal Neoplasmsboth · compare here

AO GENERIUM in Colorectal Neoplasms: 1 program

  1. afliberceptphase 3

Their studies: AO GENERIUM’s studies of Colorectal Neoplasms in search

Samsung Bioepis in Colorectal Neoplasms: 1 program

  1. afliberceptphase 2

Their studies: Samsung Bioepis’s studies of Colorectal Neoplasms in search

Lymphoma, Non-Hodgkinboth · compare here

AO GENERIUM in Lymphoma, Non-Hodgkin: 1 program

  1. afliberceptphase 3

Their studies: AO GENERIUM’s studies of Lymphoma, Non-Hodgkin in search

Samsung Bioepis in Lymphoma, Non-Hodgkin: 1 program

  1. afliberceptphase 2

Their studies: Samsung Bioepis’s studies of Lymphoma, Non-Hodgkin in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetAO GENERIUMSamsung Bioepis
VEGFAafliberceptruleafliberceptrule, Ranibizumabrule
PGFafliberceptruleafliberceptrule
A target, or a pathogen for a vaccine, known for: AO GENERIUM 1 of 3 · Samsung Bioepis 3 of 4 programs (4 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.